Anti-tumour necrosis factor therapy in seronegative spondyloarthritis.
Over 50% of ankylosing spondylitis patients treated with anti-tumour necrosis factor show a 50% improvement Infliximab, etanercept (and probably adalimumab) are equally effective Stable responses are maintained for two years If treatment is discontinued, almost all patients relapse Retreatment is pr...
Full description
Bibliographic Details
| Main Authors: |
Catherine, S,
Bowness, P |
|---|
| Format: | Journal article
|
|---|
| Language: | English |
|---|
| Published: |
2005
|
|---|